Pailai King, NP
Primary Care · San Diego, CANPI 1497187090
Payments from drug & device makers
Across 492 payments — averaging $30.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Biotronik Inc.$1K
- Cvrx, Inc.$958
- plus $6K from 32 others
What the payments were for
- Consulting fees$1,71911%
- Food & beverage$13,42588%
- Education$500%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $2,559 |
| AstraZeneca | 41 | $2,027 |
| Actelion Pharmaceuticals US, Inc. | 133 | $1,232 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 38 | $1,196 |
| Biotronik Inc. | 11 | $1,120 |
| Cvrx, Inc. | 18 | $958 |
| Novartis | 53 | $857 |
| Inari Medical, Inc. | 7 | $783 |
| Boston Scientific | 16 | $621 |
| Alnylam Pharmaceuticals Inc. | 21 | $455 |
| Kestra Medical Technology Services, Inc. | 4 | $422 |
| Philips North America LLC | 3 | $384 |
| Merck | 13 | $287 |
| Pfizer | 22 | $261 |
| Johnson & Johnson | 14 | $229 |
| Novo Nordisk | 5 | $214 |
| Boehringer Ingelheim | 11 | $202 |
| Shockwave Medical, Inc | 1 | $185 |
| Irhythm Technologies, Inc. | 4 | $168 |
| Penumbra, Inc. | 1 | $145 |
| Bridgebio Pharma, Inc. | 1 | $128 |
| Esperion Therapeutics, Inc. | 8 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $106 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $90 |
| Bayer | 6 | $85 |
| Medtronic | 2 | $47 |
| Sobi, Inc | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $41 |
| GSK | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Amarin Pharma, Inc. | 1 | $25 |
| Biosense Webster, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $20 |
| Altathera Pharmaceuticals LLC | 1 | $19 |
| Cardiva Medical, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Trevena, Inc. | 1 | $16 |
| Chiesi USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AVEIR$1,246
- FLOWTRIEVER CATHETER, S$634
- CT THROMBECTOMY SYSTEM KIT$634
- ANDEXXA$611
- LifeVest$446
- GALLANT$415
- Ambulatory Monitoring & Diagnostics Undivided$384
- Assure WCD$379
- FARXIGA$370
- Barostim Neo System$288
- Acticor 7 VR-T DX$242
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$185
- MERLIN@HOME$175
- Confirm Rx$175
- Rhythmia Mapping System$152
- Penumbra System$145
- Rivacor 7 DR-T$141
- BioMonitor$141
- Edora 8 DR-T$141
- Attruby$128
How this compares
$15,193 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $166,407 |
| XareltoRivaroxaban | 96 | $109,952 |
| MultaqDronedarone Hcl | 24 | $45,251 |
| EntrestoSacubitril/Valsartan | 23 | $28,069 |
| FarxigaDapagliflozin Propanediol | 14 | $14,943 |
| Dofetilide | 18 | $7,145 |
| Flecainide Acetate | 108 | $4,617 |
| Metoprolol Succinate | 150 | $2,306 |
| SotalolSotalol Hcl | 65 | $1,471 |
| Amiodarone Hcl | 47 | $1,050 |
| Metoprolol Tartrate | 99 | $840 |
| Valsartan | 32 | $798 |
| Atorvastatin Calcium | 63 | $651 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 18 | $631 |
| Amlodipine Besylate | 64 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $261 | $166,407122 claims |
| Johnson & JohnsonXarelto | $229 | $109,95296 claims |
| Sanofi-aventis U.S. LLCMultaq | $16 | $45,25124 claims |
| NovartisEntresto | $857 | $28,06923 claims |
| AstraZenecaFarxiga | $2,027 | $14,94314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in San Diego
- Kathryn CooperSan Diego$31K
- Ashley LoweSan Diego$19K
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Joann BallPalm Desert$56K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Vanessa LeeLong Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.